In a series of 248 tumor samples obtained from image-guided biopsies from patients diagnosed with ductal carcinoma of the breast, we attempted to identify biomarkers that predict microinfiltration at definitive surgery or relapse during follow-up. For this, we used immunohistochemical methods, followed by automated image analyses, to measure the mean diameter of nuclei (which correlates with ploidy), the phosphorylation of eukaryotic initiation factor 2α (eIF2α, which reflects endoplasmic reticulum stress) as well as the density and ratio of CD8 cytotoxic T lymphocytes and FOXP3 regulatory T cells. The median nuclear diameter of malignant cells correlated with eIF2α phosphorylation (in cancerous tissue), which in turn correlated with the density of the CD8 infiltrate and the CD8/FOXP3 ratio (both in cancerous and the adjacent non-cancerous parenchyma). Neither microinfiltration nor lymph node involvement was associated with the probability of relapse. Both correlated positively with the CD8/FOXP3 ratio in the malignant area. In contrast, relapse was associated with a paucity of the CD8 infiltrate as well as an unfavorable CD8/FOXP3 ratio, both in malignant and non-malignant parenchyma. The combined analysis of the CD8/FOXP3 ratio in cancerous and non-cancerous tissues revealed a significant impact of their interaction on the probability of relapse, but not on the presence of microinfiltration or lymph node metastasis. Altogether, these results support the idea of an immunosurveillance system that determines the risk of relapse in ductal carcinoma of the breast.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087306 | PMC |
http://dx.doi.org/10.1080/2162402X.2016.1218106 | DOI Listing |
Int J Radiat Oncol Biol Phys
January 2025
Department of Urology, University of Tsukuba, Ibaraki, Japan. Electronic address:
Purpose: Bladder preservation therapy in combination with atezolizumab and radiation therapy (BPT-ART) trial, which was a multicenter, open-label, single-arm phase II study, showed a promisingly high interim clinical complete response (cCR) rate of 84.4% (38/45). In the present study, we aimed to identify potential tissue biomarkers for achieving cCR via BPT-ART.
View Article and Find Full Text PDFAnn Surg Oncol
December 2024
Department of Pathology, Saitama Cancer Center, Saitama, Japan.
Background: Little is known about the survival impacts of mitochondrial status in esophageal squamous cell carcinoma (ESCC) patients who undergo neoadjuvant chemotherapy (NAC) followed by surgery.
Methods: In total, 260 pre-NAC samples from ESCC patients were analyzed. Mitochondrial status was estimated employing an objective, immunohistochemistry-based system (Mito-score).
Breast Cancer Res Treat
November 2024
Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL, 60637, USA.
Anticancer Res
November 2024
Clinical Research and Innovation Department, Centre Jean Perrin, Clermont-Ferrand, France.
Background/aim: Triple-negative breast cancer (TNBC) is the most heterogeneous breast cancer subtype, posing numerous challenges in clinical decision-making. Biomarkers are essential to personalize management of TNBC patients. While tumor infiltrating lymphocytes (TILs) are validated prognostic biomarkers, the requirement for tumor biopsy limits their routine use.
View Article and Find Full Text PDFAnticancer Res
November 2024
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Background/aim: Nestin, an intermediate filament protein expressed in stem/progenitor cells of the developing central nervous system, is involved in the progression and poor prognosis of various malignancies. Difficulties in small-cell lung cancer (SCLC) tissue biopsy reduce the accuracy of immunohistochemistry analyses; therefore, evaluating nestin in blood samples is preferred in clinical practice. This study examined the clinical significance of plasma nestin levels in SCLC.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!